Investing.com - Transcode Therapeutics (NASDAQ: RNAZ) reported fourth quarter EPS of $-0.38, in line with the analyst estimate of $-0.38. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.00.
Transcode Therapeutics's stock price closed at $0.34. It is down -49.80% in the last 3 months and down -88.62% in the last 12 months.
Transcode Therapeutics saw 0 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Transcode Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Transcode Therapeutics's Financial Health score is "weak performance".
Check out Transcode Therapeutics's recent earnings performance, and Transcode Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar